Loading
A phase 2 trial of Namodenoson 25mg in pancreatic ductal adenocarcinoma, run by Can-Fite BioPharma, now recruiting.
Namodenoson Treatment of Advanced Pancreatic Cancer is a phase 2 interventional study registered as NCT06387342 by Can-Fite BioPharma, with 20 participants planned, started 2024-11-10 and due to reach its primary completion in 2026-07-15. Interventions recorded: Namodenoson 25mg.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Can-Fite BioPharma and the tag pipeline.
Shares Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/